Therefore, early and accurate prediction of tumor shrinkage patterns in HR+/HER2- BC patients after NAC is critical for ensuring patients benefit from NAC with the goal of breast conservation while avoiding overtreatment and ineffective therapy. This evidence concerns the gene ERBB2 and neoplasm.